Literature DB >> 30303355

Therapy for relapsed multiple myeloma.

Mohammed A Aljama1, M Hasib Sidiqi1, David Dingli2.   

Abstract

Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30303355     DOI: 10.23736/S0031-0808.18.03542-5

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  1 in total

1.  Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis.

Authors:  Huijuan Wang; Chuanying Geng; Huixing Zhou; Zhiyao Zhang; Wenming Chen
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.